PE-22-28
PE-22-28 is a seven-amino-acid peptide sold as a mood and focus compound. It was designed by French researchers as an improved version of a natural peptide called spadin. All of the evidence is in rodents.
- Legal lane: not FDA-approved. Sold as a research chemical.
- Evidence grade: D
- Form: nasal spray or injection as sold
- Established human dose: none
What it is
A shortened analog of spadin. It blocks a potassium channel in nerve cells called TREK-1, which makes those cells more responsive. In laboratory tests it blocked the channel far more strongly than spadin and lasted longer in the body.
What the evidence shows
The 2017 paper that introduced it reported antidepressant-like behavior in mice and signs of new nerve cell growth. The authors called it a promising alternative to spadin for treating depression.
No human trial of PE-22-28 or of spadin has been completed or registered, according to a clinical summary last updated in September 2026.
Legal status
- Not FDA-approved for any use.
- Not one of the six peptides in the October 2026 compounding policy.
- What is sold online is a research chemical.
Reported dosing
We do not publish a protocol for this compound.
No dose has been established in people.
Safety
- The channel it blocks is also found in the heart, pancreas and gut. The effects of blocking it throughout the body are uncharacterized.
- Depression is treatable with therapies that have been tested. An untested research chemical is not a safe substitute, and stopping a prescribed antidepressant to try one is risky.
- Products sold as research chemicals have no verified contents or sterility.
Common questions
Has PE-22-28 been tested in humans?
No. The evidence is from rodents.
What does PE-22-28 do?
It blocks the TREK-1 potassium channel, which produced antidepressant-like effects in mice.
Is PE-22-28 legal?
It is not FDA-approved and is sold only as a research chemical.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.